ClinicalTrials.gg
RecruitingNCT07502508Updated Oct 20, 2026

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

A Phase 2 interventional study of icovamenib 100 mg and Placebo in Type 2 Diabetes, sponsored by Biomea Fusion Inc.. Recruiting at 20 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Biomea Fusion Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Oct 20, 2026Eligibility revised3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Planned enrollment
1,725th of 2,957
60 · median 90
Started
2026
with 152 others
Phase 2
391 of 3,304
24 open now
Primary completion
2027-06
later than 261 of 476 live
Registered
3,213th of 3,304
by date

Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 1,725th largest by planned enrollment of the 2,957 interventional ones that give a count, is one of 153 that started in 2026, is one of 391 in phase 2, reaches primary completion later than 261 of the 476 other live ones, and was the 3,213th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

338 more — sign in →

All 343 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite GLP-1-based therapy.

Read the detailed description

This study is a 52-week, phase 2 trial designed to examine whether treatment with icovamenib in participants with T2D who are currently on a GLP-1-based therapy will result in a greater reduction in HbA1c than GLP-1 based therapy alone. The current trial investigates participants who have used GLP-1 for at least 3 months prior to screening whose HbA1c remains above the target established by the ADA.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Type 2 Diabetes
04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Males or females, age ≥18 years and ≤75 years
  2. Have been diagnosed with T2D
  3. Taking FDA-approved GLP-1 based therapy (administered as subcutaneous injection) and have been treated with lifestyle management and 0 to 2 additional antihyperglycemic medications (metformin and/or SGLT2 inhibitor) with a stable dose of all medications for at least 3 months prior to screening
  4. Have ≥7.0 and ≤10.5%
  5. Have a 25 to 45 kg/m2
  6. Female participants of must have a negative pregnancy test, must be non-lactating, must be willing to have additional pregnancy tests during the study, must agree to the sex and requirements.
  7. Willing and able to provide written, signed and be willing and able to comply with all study procedures and tests.

Key Exclusion Criteria:

  1. Have type 1 diabetes mellitus or a secondary form of diabetes
  2. Have a history of diabetic ketoacidosis or hyperosmolar coma in the 6 months prior to screening
  3. Have a history of severe hypoglycemia (defined by the occurrence of hypoglycemia symptoms requiring the assistance of another person for recovery) in the 6 months prior to screening or a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms as judged by the investigator
  4. Have personal or family history (first-degree relative) of MEN1 or MEN2 or medullary thyroid carcinoma
  5. Use of any of the following in the 3 months prior to screening: compounded GLP-1-based therapy, sulfonylureas, meglitinides, thiazolidinediones, alpha glucosidase inhibitor, DPP4I, bile acid sequestrants, dopamaine-2 agonists, amylin, or insulin
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Arm A: icovamenib 100 mg

    Starting on Day 1, participants will receive icovamenib or placebo 100 mg QD in addition to their currently prescribed GLP-1or GIP/GLP-1 RA based regimen. Treatment will last for 12 weeks. At Week 12, participants will continue on a stable dose of their baseline Ozempic-based regimen. The total duration of the trial is approximately 57 weeks (including screening and follow-up)

    Drug: icovamenib 100 mg

  • Placebo comparator
    Arm B: matching placebo 100 mg

    Starting on Day 1, participants will receive matching placebo QD in addition to their currently prescribed GLP-1-based regimen. Treatment will last for 12 weeks. At Week 12, participants will continue on a stable dose of allowable GLP-1-based regimen. The total duration of the trial is approximately 57 weeks (including screening and follow-up).

    Drug: Placebo

Interventions

This study also gives Semaglutide. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. To demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic control

    Mean change in HbA1c from baseline

    Time frame: 26 weeks

07

Study locations

20 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 14 months is close to that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Mar 31, 2026
StartActual
Apr 30, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jul 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 United States)
  • Centricity Research, Endocrine Consultants PC · Columbus, United States
  • Centricity Research, Lucas Research, Inc. · Morehead City, United States
  • Synergy Group Medical · Missouri City, United States
Oct 20, 2026
Eligibility
Maximum age 70 Years→75 Years; 5 criteria edited, 3 removed
What changed in the criteria
  • EditedMales or females, age ≥18 years and ≤7075 years
  • EditedTaking OzempicFDA-approved GLP-1 based therapy (semaglutideadministered as subcutaneous injection) and have been treated with lifestyle management and 0 to 2 additional antihyperglycemic medications (metformin and/or SGLT2 inhibitor) with a stable dose of all medications for at least 3 months prior to screening
  • RemovedIf participants are taking metformin, they must be on a minimum stable dose of ≥500 mg/day
  • RemovedParticipants must be on a minimum stable dose of Ozempic ≥0.5 mg/week
  • EditedHave HbA1c ≥7.50 and ≤910.5%
  • EditedHave a BMI 25 to 4045 kg/m2
  • EditedUse of any of the following in the 3 months prior to screening: compounded GLP-1 RA other than Ozempic (semaglutide injection), dual GIP/GLP-1 RA-based therapy, sulfonylureas, meglitinides, thiazolidinediones, alpha glucosidase inhibitor, DPP4I, bile acid sequestrants, dopamaine-2 agonists, amylin, or insulin in the 3 months prior to screening
  • RemovedHave FPG ≥240 mg/dL
Oct 20, 2026
Secondary outcomes
9 removed
What changed in the outcomes
  • RemovedTo demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic controlTime frame: 12 weeks
  • RemovedTo demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic controlTime frame: 52 weeks
  • RemovedTo compare the change in fasting plasma glucose with icovamenib versus placebo during the off-treatment Follow-up PeriodTime frame: 26 weeks
  • RemovedTo compare the safety and tolerability of icovamenib versus placeboTime frame: 52 weeks
  • RemovedTo compare the safety and tolerability of icovamenib versus placeboTime frame: 52 weeks
  • RemovedTo compare the safety and tolerability of icovamenib versus placeboTime frame: 52 weeks
  • RemovedTo compare the safety and tolerability of icovamenib versus placeboTime frame: 12 weeks
  • Removedother outcomeTo characterize the pharmacokinetics of icovamenibTime frame: 10 weeks
  • Removedother outcomeTo characterize the pharmacokinetics of icovamenibTime frame: 10 weeks
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    3 sites added
    Show 3 added (3 United States)
    • Centricity Research, Endocrine Consultants PC · Columbus, United States
    • Centricity Research, Lucas Research, Inc. · Morehead City, United States
    • Synergy Group Medical · Missouri City, United States
    Eligibility Maximum age 70 Years→75 Years; 5 criteria edited, 3 removed
    What changed in the criteria
    • EditedMales or females, age ≥18 years and ≤7075 years
    • EditedTaking OzempicFDA-approved GLP-1 based therapy (semaglutideadministered as subcutaneous injection) and have been treated with lifestyle management and 0 to 2 additional antihyperglycemic medications (metformin and/or SGLT2 inhibitor) with a stable dose of all medications for at least 3 months prior to screening
    • RemovedIf participants are taking metformin, they must be on a minimum stable dose of ≥500 mg/day
    • RemovedParticipants must be on a minimum stable dose of Ozempic ≥0.5 mg/week
    • EditedHave HbA1c ≥7.50 and ≤910.5%
    • EditedHave a BMI 25 to 4045 kg/m2
    • EditedUse of any of the following in the 3 months prior to screening: compounded GLP-1 RA other than Ozempic (semaglutide injection), dual GIP/GLP-1 RA-based therapy, sulfonylureas, meglitinides, thiazolidinediones, alpha glucosidase inhibitor, DPP4I, bile acid sequestrants, dopamaine-2 agonists, amylin, or insulin in the 3 months prior to screening
    • RemovedHave FPG ≥240 mg/dL
    Secondary outcomes 9 removed
    What changed in the outcomes
    • RemovedTo demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic controlTime frame: 12 weeks
    • RemovedTo demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic controlTime frame: 52 weeks
    • RemovedTo compare the change in fasting plasma glucose with icovamenib versus placebo during the off-treatment Follow-up PeriodTime frame: 26 weeks
    • RemovedTo compare the safety and tolerability of icovamenib versus placeboTime frame: 52 weeks
    • RemovedTo compare the safety and tolerability of icovamenib versus placeboTime frame: 52 weeks
    • RemovedTo compare the safety and tolerability of icovamenib versus placeboTime frame: 52 weeks
    • RemovedTo compare the safety and tolerability of icovamenib versus placeboTime frame: 12 weeks
    • Removedother outcomeTo characterize the pharmacokinetics of icovamenibTime frame: 10 weeks
    • Removedother outcomeTo characterize the pharmacokinetics of icovamenibTime frame: 10 weeks
    + 4 other changes: verification date, description, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07502508
Lead sponsor
Biomea Fusion Inc.
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Apr 30, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Biomea Fusion Inc.
Contact
clinicaltrials@biomeafusion.com
8442450490

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icovamenib

Start the discussion